Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference
February 26, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday, March...
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
January 03, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various...
Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
December 17, 2018 08:36 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
December 11, 2018 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial,...
Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis
December 06, 2018 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline consisting of five product candidates...
Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress
November 01, 2018 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept pivotal Phase 3 clinical trial initiating this year– Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing– KPL-716 advancing into multiple chronic...
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Single-doses were well-tolerated and showed reduction in pruritus - - Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis - HAMILTON, BERMUDA,...
Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
August 29, 2018 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring,...
Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference
August 28, 2018 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, BERMUDA, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will be presenting at the 2018 Wells Fargo Healthcare Conference on...
Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress
August 06, 2018 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept advancing toward pivotal Phase 3 clinical trial in 2H 2018 following recent End-of-Phase 2 communication with FDA – – KPL-716 single-dose Phase 1a/1b Last Subject Last Visit achieved;...